निलोटिनिब और रिफैक्सिमिन का इंटरैक्शन

• Concomitant P-glycoprotein (P-gp) inhibitors (e.g., cyclosporine): Caution should be exercised when concomitant use of XIFAXAN and a P-glycoprotein inhibitor is needed.

Concomitant Use with P-glycoprotein Inhibitors Concomitant administration of drugs that are P-glycoprotein (P-gp) inhibitors with XIFAXAN can substantially increase the systemic exposure to rifaximin.

Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed.

In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin [see Drug Interactions ( 7.1 ), Clinical Pharmacology ( 12.3 )].

P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin.